Real-World Outcomes of Immune Checkpoint Inhibitors in Melanoma, Including Acral and Mucosal Subtypes: A Retrospective Cohort Study From a Latin American Center

Background

Real-world evidence on immune checkpoint inhibitors (ICIs) in Latin American patients with melanoma remains limited, particularly for acral and mucosal subtypes. We evaluated survival, radiologic response, immune-related adverse events (irAEs), and exploratory factors associated with outcomes in a Colombian cohort.